ASCO 2017 | LAG-3 antibody combination in immunotherapy-treated melanoma

Paolo Ascierto, MD, from Istituto Nazionale Tumori, Napoli, Italy, discusses the positive outcomes from a Phase I trial involving the treatment of patients with melanoma with an anti-lymphocyte activation gene-3 (LAG-3) antibody, BMS-986016, as well as anti-PD1/PD-1 therapy (NCT01968109). He reports a good safety profile and progression of disease in treated patients and believes that this combination may be promising in the future as it is the first regimen that can overcome treatment resistance in melanoma patients. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.